127 related articles for article (PubMed ID: 12885412)
1. Prevention of passively transferred experimental autoimmune myasthenia gravis by an in vitro selected RNA aptamer.
Hwang B; Han K; Lee SW
FEBS Lett; 2003 Jul; 548(1-3):85-9. PubMed ID: 12885412
[TBL] [Abstract][Full Text] [Related]
2. Improvement of RNA aptamer activity against myasthenic autoantibodies by extended sequence selection.
Hwang B; Lee SW
Biochem Biophys Res Commun; 2002 Jan; 290(2):656-62. PubMed ID: 11785949
[TBL] [Abstract][Full Text] [Related]
3. Treatment of passively transferred experimental autoimmune myasthenia gravis using papain.
Poulas K; Tsouloufis T; Tzartos SJ
Clin Exp Immunol; 2000 May; 120(2):363-8. PubMed ID: 10792389
[TBL] [Abstract][Full Text] [Related]
4. Prevention of passively transferred experimental autoimmune myasthenia gravis by Fab fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor.
Papanastasiou D; Poulas K; Kokla A; Tzartos SJ
J Neuroimmunol; 2000 May; 104(2):124-32. PubMed ID: 10713351
[TBL] [Abstract][Full Text] [Related]
5. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor.
Barchan D; Asher O; Tzartos SJ; Fuchs S; Souroujon MC
Eur J Immunol; 1998 Feb; 28(2):616-24. PubMed ID: 9521072
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis.
Martínez-Martínez P; Losen M; Duimel H; Frederik P; Spaans F; Molenaar P; Vincent A; De Baets MH
Am J Pathol; 2007 Feb; 170(2):644-57. PubMed ID: 17255332
[TBL] [Abstract][Full Text] [Related]
8. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
[TBL] [Abstract][Full Text] [Related]
9. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4.
Im SH; Barchan D; Maiti PK; Fuchs S; Souroujon MC
J Immunol; 2001 Jun; 166(11):6893-8. PubMed ID: 11359850
[TBL] [Abstract][Full Text] [Related]
10. Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells.
Xu L; Villain M; Galin FS; Araga S; Blalock JE
Cell Immunol; 2001 Mar; 208(2):107-14. PubMed ID: 11333143
[TBL] [Abstract][Full Text] [Related]
11. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
Araga S; Galin FS; Kishimoto M; Adachi A; Blalock JB
J Immunol; 1996 Jul; 157(1):386-92. PubMed ID: 8683141
[TBL] [Abstract][Full Text] [Related]
12. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.
Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H
Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409
[TBL] [Abstract][Full Text] [Related]
13. Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies.
Lee SW; Sullenger BA
Nat Biotechnol; 1997 Jan; 15(1):41-5. PubMed ID: 9035104
[TBL] [Abstract][Full Text] [Related]
14. Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats.
Yao X; Zhao J; Kong Q; Xie X; Wang J; Sun B; Xu L; Mu L; Li H
Immunol Invest; 2018 Oct; 47(7):712-724. PubMed ID: 29944018
[TBL] [Abstract][Full Text] [Related]
15. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat.
Meinl E; Klinkert WE; Wekerle H
Am J Pathol; 1991 Nov; 139(5):995-1008. PubMed ID: 1951638
[TBL] [Abstract][Full Text] [Related]
16. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor.
Tzartos S; Hochschwender S; Vasquez P; Lindstrom J
J Neuroimmunol; 1987 Jun; 15(2):185-94. PubMed ID: 3495549
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
Losen M; Stassen MH; Martínez-Martínez P; Machiels BM; Duimel H; Frederik P; Veldman H; Wokke JH; Spaans F; Vincent A; De Baets MH
Brain; 2005 Oct; 128(Pt 10):2327-37. PubMed ID: 16150851
[TBL] [Abstract][Full Text] [Related]
18. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
[TBL] [Abstract][Full Text] [Related]
19. Sequence and structural features of RNA aptamer against myasthenic autoantibodies.
Cho JS; Lee SW
Oligonucleotides; 2009 Sep; 19(3):273-80. PubMed ID: 19642914
[TBL] [Abstract][Full Text] [Related]
20. Novel complement inhibitor limits severity of experimentally myasthenia gravis.
Soltys J; Kusner LL; Young A; Richmonds C; Hatala D; Gong B; Shanmugavel V; Kaminski HJ
Ann Neurol; 2009 Jan; 65(1):67-75. PubMed ID: 19194881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
